Federal Register of Legislation - Australian Government

Primary content

PB 63 of 2021 Determinations/Health as made
This instrument amends the National Health (Continued Dispensing – Emergency Measures) Determination 2020 to make changes to the pharmaceutical benefits eligible to be provided as a Continued Dispensing supply to reflect amendments to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), which commence on the same day.
Administered by: Health
Registered 29 Jun 2021
Tabling HistoryDate
Tabled HR03-Aug-2021
Tabled Senate03-Aug-2021
Date of repeal 19 Oct 2021
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 63 of 2021

 

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated    29 June 2021

 

 

 

 

           

NIKOLAI TSYGANOV                 

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

                                           


 

 

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

 

 

 


1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 6).

(2) This instrument may also be cited as PB 63 of 2021.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 July 2021.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1]        Schedule 1, entry for Captopril

omit:

 

Tablet 25 mg

Oral

 

Tablet 50 mg

Oral

[2]        Schedule 1, entry for Guselkumab

insert as first entry:

 

Injection 100 mg in 1 mL single use pre-filled pen

Injection

[3]        Schedule 1, after entry for Hydromorphone in the form Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 200 mL

insert:

 

Oral solution containing hydromorphone hydrochloride 1 mg per mL, 473 mL

Oral

[4]        Schedule 1, after entry for Imipramine in the form Tablet containing imipramine hydrochloride 10 mg

insert:

 

Tablet containing imipramine hydrochloride 10 mg USP

Oral

[5]        Schedule 1, after entry for Indometacin in the form Suppository 100 mg

insert:

Infliximab

Solution for injection 120 mg in 1 mL pre-filled pen

Injection

 

Solution for injection 120 mg in 1 mL pre-filled syringe

Injection

[6]        Schedule 1, omit entry for Interferon alfa‑2a


 

[7]        Schedule 1, after entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity

insert:

 

Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity

Oral

[8]        Schedule 1, entry for Progesterone

insert as first entry:

 

Capsule 200 mg

Vaginal

[9]        Schedule 1, after entry for Tofacitinib in the form Tablet 5 mg

insert:

 

Tablet 10 mg

Oral